We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exelixis (EXEL) Inks Collaboration Deal to Test XL092 Combo in UC
Read MoreHide Full Article
Exelixis, Inc. (EXEL - Free Report) announced that it has entered into a collaboration and supply agreement with Germany’s Merck KGaA and pharma giant Pfizer (PFE - Free Report) for the ongoing phase Ib dose-escalation study – STELLAR-001.
Per the latest development, three new cohorts will be added to the above-mentioned study, which will evaluate the safety and tolerability of Exelixis’ novel next-generation tyrosine kinase inhibitor, XL092, in combination with Pfizer’s anti-PD-L1 immune checkpoint inhibitor (“ICI”), Bavencio (avelumab), for treating patients with locally-advanced or metastatic urothelial carcinoma (“UC”).
Notably, the STELLAR-001 study is being sponsored by Exelixis while Merck KGaA and Pfizer are providing Bavencio for use in the same. Bavencio is being co-developed and co-commercialized by Pfizer and Merck KGaA.
Shares of Exelixis have rallied 13.9% so far this year compared with the industry’s increase of 3.9%.
We remind investors that Exelixis is currently enrolling patients in the dose-escalation cohorts of the phase Ib clinical study of XL092 in combination with Roche’s (RHHBY - Free Report) immunotherapy, Tecentriq (atezolizumab).
In October 2020, the first patient was enrolled in the dose-escalation cohort of the combination arm of the phase I study evaluating the safety, tolerability, PK and preliminary anti-tumor activity of XL092, both alone and in combination with Tecentriq in patients with advanced solid tumors.
Zacks Rank & Stock to Consider
Exelixis currently carries a Zacks Rank #4 (Sell).
Repligen’ earnings estimates have been revised 15.1% upward for 2021 and 9.8% for 2022 over the past 60 days. The stock has inched up 4.4% year to date.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
Image: Bigstock
Exelixis (EXEL) Inks Collaboration Deal to Test XL092 Combo in UC
Exelixis, Inc. (EXEL - Free Report) announced that it has entered into a collaboration and supply agreement with Germany’s Merck KGaA and pharma giant Pfizer (PFE - Free Report) for the ongoing phase Ib dose-escalation study – STELLAR-001.
Per the latest development, three new cohorts will be added to the above-mentioned study, which will evaluate the safety and tolerability of Exelixis’ novel next-generation tyrosine kinase inhibitor, XL092, in combination with Pfizer’s anti-PD-L1 immune checkpoint inhibitor (“ICI”), Bavencio (avelumab), for treating patients with locally-advanced or metastatic urothelial carcinoma (“UC”).
Notably, the STELLAR-001 study is being sponsored by Exelixis while Merck KGaA and Pfizer are providing Bavencio for use in the same. Bavencio is being co-developed and co-commercialized by Pfizer and Merck KGaA.
Shares of Exelixis have rallied 13.9% so far this year compared with the industry’s increase of 3.9%.
We remind investors that Exelixis is currently enrolling patients in the dose-escalation cohorts of the phase Ib clinical study of XL092 in combination with Roche’s (RHHBY - Free Report) immunotherapy, Tecentriq (atezolizumab).
In October 2020, the first patient was enrolled in the dose-escalation cohort of the combination arm of the phase I study evaluating the safety, tolerability, PK and preliminary anti-tumor activity of XL092, both alone and in combination with Tecentriq in patients with advanced solid tumors.
Zacks Rank & Stock to Consider
Exelixis currently carries a Zacks Rank #4 (Sell).
A better-ranked stock in the biotech sector is Repligen Corporation (RGEN - Free Report) , which has a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Repligen’ earnings estimates have been revised 15.1% upward for 2021 and 9.8% for 2022 over the past 60 days. The stock has inched up 4.4% year to date.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 3 crypto-related stocks now >>